Results for tag: "Hyperparathyroidism Drug"

Hyperparathyroidism is a disorder of the endocrine system caused by an overactive parathyroid gland. It is characterized by an abnormally high level of parathyroid hormone in the blood, leading to an increase in calcium levels. Treatment for hyperparathyroidism typically involves medications that reduce the production of parathyroid hormone, as well as lifestyle changes to reduce the risk of complications. Endocrine and Metabolic Disorders Drugs are used to treat a variety of endocrine and metabolic disorders, including hyperparathyroidism. Common medications used to treat hyperparathyroidism include calcimimetics, which reduce the production of parathyroid hormone, and bisphosphonates, which reduce the absorption of calcium in the bones. Other medications, such as vitamin D supplements, may also be prescribed to help regulate calcium levels. The Hyperparathyroidism Drug market is a subset of the larger Endocrine and Metabolic Disorders Drugs market. It is composed of a variety of medications used to treat hyperparathyroidism, as well as lifestyle changes and supplements. Companies in the market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more